Mr. Donald McCaffrey reports

RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS

Resverlogix Corp. has held its annual meeting of shareholders in Calgary, Alta.

During business proceedings at the meeting, shareholders elected five board members until the next annual meeting. The voting results of shares represented at the meeting for individual directors are set out in the attached table.

                      VOTING RESULTS FOR ELECTION OF DIRECTORS

                        Votes for   Votes withheld   Per cent for   Per cent withheld

Donald J. McCaffrey   125,007,142        7,326,179          94.46%               5.54%      
Shawn Lu              126,119,539        6,213,782          95.30%               4.70%      
Kelly McNeill         125,955,508        6,377,813          95.18%               4.82%      
Siu Lun (Dicky) To    127,354,197        4,979,124          96.24%               3.76%      
Kenneth Zuerblis      127,166,543        5,166,778          96.10%               3.90%      

Resverlogix shareholders approved all resolutions outlined in the notice of meeting and management information circular dated May 11, 2022. The information circular is available on SEDAR and on the Resverlogix website.

A webcast archive of the executive presentation portion of the meeting will be available.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. It aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated co-morbidities and COVID-19.

Resverlogix common shares trade on the Toronto Stock Exchange (RVX).